NeOnc Adds Abu Dhabi Banking Veteran to Board Amid Brain Cancer Drug Push
Event summary
- NeOnc appointed Ali Alabedin, Head of Islamic Banking Group at First Abu Dhabi Bank, to its Board of Directors on October 9, 2026.
- Dr. Steven L. Giannotta stepped down from the board but remains on the Scientific Advisory Board.
- NeOnc's NEO212 drug completed Phase 1 dose escalation and is advancing toward Phase 2, with UAE investigational new drug authorization granted.
- The company reported 48.9% six-month progression-free survival in its NEO100 Phase 2a study, exceeding a 20% benchmark.
- NeOnc redeemed its outstanding Series A convertible preferred stock on September 17, 2026, eliminating potential dilution.
The big picture
NeOnc's board addition reflects a strategic pivot toward financial and international growth expertise as it navigates the complex challenge of delivering therapies across the blood-brain barrier. The company's progress in brain cancer drug development, particularly with NEO212, positions it at the forefront of addressing one of the most difficult-to-treat cancers. The recent capital structure adjustment and positive clinical data further solidify its standing in the biopharmaceutical sector.
What we're watching
- Regulatory Feedback
- How the November 17, 2026, FDA meeting on NEO212 will shape Phase 2 trial design and regulatory pathways.
- UAE Expansion
- Whether NeOnc can secure UAE ethics clearance and begin patient enrollment for NEO212 trials.
- Clinical Momentum
- The pace at which NeOnc advances follow-up FDA engagement for NEO100 based on Phase 2a results.
Related topics